🇺🇸 Amikacin (Inhalation) in United States
6 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 6
Most-reported reactions
- Acute Kidney Injury — 1 report (16.67%)
- Condition Aggravated — 1 report (16.67%)
- Drug Ineffective — 1 report (16.67%)
- Hypercapnia — 1 report (16.67%)
- Lung Infection — 1 report (16.67%)
- Respiratory Gas Exchange Disorder — 1 report (16.67%)
Other Infectious Disease approved in United States
Frequently asked questions
Is Amikacin (Inhalation) approved in United States?
Amikacin (Inhalation) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Amikacin (Inhalation) in United States?
The University of Queensland is the originator. The local marketing authorisation holder may differ — check the official source linked above.